Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Anti-Parkinson Drugs Market Through 2034?

The market size for anti-parkinson drugs has experienced considerable growth recently. The forecast suggests an upsurge from $10.37 billion in 2024 to approximately $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. Factors responsible for this progression during the historical period include an aging population, surging disease prevalence, improvements in healthcare infrastructure, and advancements in medical research.

The market for anti-Parkinson’s medications is forecasted to experience substantial expansion in the forthcoming years. It is estimated to increase to a value of $13.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this projected growth during the forecast period include enhanced awareness, advancements in biotechnology, and emerging markets. The future trends within the same frame include investments in research and development, the advent of personalized medicine, therapies that modify the disease course, drug repurposing, the rise of telemedicine and remote patient monitoring, the impact of biosimilars, and the role of research collaborations.

Which Factors Are Enhancing the Growth of the Anti-Parkinson Drugs Market?

The escalating number of older adults and the rising instances of Parkinson’s disease is anticipated to fuel the demand for the anti-Parkinson’s drugs market. Parkinson’s disease is predominantly observed in individuals over 60 years old. For example, in October 2022, the World Health Organization, an American health institution, reported that 1 in every 6 people globally will be aged 60 or above by the year 2030, and this figure is expected to double (reaching 2.1 billion) by 2050. Consequently, the expansion of the elderly population is catalyzing the anti-Parkinson’s drugs market growth.

Explore Comprehensive Insights Into The Global Anti-Parkinson Drugs Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Anti-Parkinson Drugs Market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Which Current Trends Are Having the Most Impact on the Anti-Parkinson Drugs Market?

Major firms in the anti-Parkinson drugs market are concentrating their efforts on creating cutting-edge therapeutic solutions like motor fluctuations and dyskinesia with a focus on enhancing symptom management and reducing adverse effects. Motor fluctuations and dyskinesia typically make Parkinson’s disease treatment more complex and have an impact on patient welfare. For example, in January 2024, AbbVie Inc., an American pharmaceutical firm, introduced PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa), the first-ever subcutaneous 24-hours infusion therapy specially designed for advanced Parkinson’s disease, focuses on extreme motor fluctuations and dyskinesia when other treatments cannot provide sufficient help. This solution continuously provides levodopa, potentially maximizing ‘on’ time and improving symptom management.

Secure Your Global Anti-Parkinson Drugs Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

How Are the Key Segments of the Anti-Parkinson Drugs Market Driving Opportunities and Innovations?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

Which Regions Are Key Players in the Growth of the Anti-Parkinson Drugs Market?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Definition of the Anti-Parkinson Drugs Market Impacting Future Growth?

Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.

Browse Through More Similar Reports By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Brain Monitoring Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-monitoring-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: